Meningococcal Vaccines: Challenges and Prospects. [PDF]
Bagwe P +5 more
europepmc +1 more source
Michael Bröker, Brian Cooper, Lisa M DeTora, Jeffrey J StoddardGlobal Medical Affairs, Novartis Vaccines and Diagnostics, Marburg, Germany, and Cambridge, MA, USAAbstract: Worldwide, invasive meningococcal disease affects about 500,000 people ...
Bröker M +3 more
doaj
Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt. [PDF]
Sundaram ME +6 more
europepmc +1 more source
Economic evaluation of meningococcal vaccines: considerations for the future. [PDF]
Christensen H +17 more
europepmc +1 more source
Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib. [PDF]
Ishowo-Adejumo R +3 more
europepmc +1 more source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study. [PDF]
Hoberman A +11 more
europepmc +1 more source
Meningococcal ACWY vaccines \ue2\u20ac\u201dMenACWY and MPSV4: what you need to know
Meningococcal disease is a serious illness caused by a type of bacteria called Neisseria meningitidis. It can lead to meningitis (infection of the lining of the brain and spinal cord) and infections of the blood.
core
<i>Neisseria meningitidis</i> bacteraemia and lobar pneumonia in a previously healthy, fully immunised (including meningococcal vaccines) Irish teenager. [PDF]
Lacey S, Moylett E.
europepmc +1 more source

